Lv1
54 积分 2026-04-20 加入
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
3个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
3个月前
已完结
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
3个月前
已完结
Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations
4个月前
已完结
Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations
4个月前
已完结
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
5个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
6个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
6个月前
已完结
皖公网安备34019202002308
